Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||fallopian tube cancer||not applicable||CRLX101 + Paclitaxel||Phase Ib/II||Actionable||In a Phase Ib/II trial, CRLX101 in combination with weekly Taxol (paclitaxel) resulted in an objective response rate (ORR) of 31.6% (6/19, 1 complete response, 5 partial responses) and a median progression-free survival of 5.4 months in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer, although the ORR was not superior to that of historical control (PMID: 33390325; NCT02389985).||33390325|